Solve M.E. Funds GLP-1 and Immune Target Studies to Accelerate ME/CFS and Long Covid Breakthroughs
PR Newswire —
The Solve ME/CFS Catalyst Award-winning studies will fast-track clinical and immunological studies aimed at delivering new treatment strategies and diagnostic insights for ME/CFS and Long Covid, conditions still lacking FDA-approved therapies. LOS ANGELES, Feb. 24, 2026 /PRNewswire/ --...